PROSPERO International prospective register of systematic reviews |
Review title and timescale | |||||||||||||||||||||||||||||||||||||
1 |
Review titleGive the working title of the review. This must be in English. Ideally it should state succinctly the interventions or exposures being reviewed and the associated health or social problem being addressed in the review.Prognostic and predictive value of neutrophil to lymphocyte ratio in ovarian cancer |
||||||||||||||||||||||||||||||||||||
2 |
Original language titleFor reviews in languages other than English, this field should be used to enter the title in the language of the review. This will be displayed together with the English language title. |
||||||||||||||||||||||||||||||||||||
3 |
Anticipated or actual start dateGive the date when the systematic review commenced, or is expected to commence.27/11/2016 |
||||||||||||||||||||||||||||||||||||
4 |
Anticipated completion dateGive the date by which the review is expected to be completed.31/01/2017 |
||||||||||||||||||||||||||||||||||||
5 |
Stage of review at time of this submissionIndicate the stage of progress of the review by ticking the relevant boxes. Reviews that have progressed beyond the point of completing data extraction at the time of initial registration are not eligible for inclusion in PROSPERO. This field should be updated when any amendments are made to a published record. |
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Provide any other relevant information about the stage of the review here.National Natural Science Foundation of China (no. 81401187). |
|||||||||||||||||||||||||||||||||||||
Review team details | |||||||||||||||||||||||||||||||||||||
6 |
Named contactThe named contact acts as the guarantor for the accuracy of the information presented in the register record.Quan Zhou |
||||||||||||||||||||||||||||||||||||
7 |
Named contact emailEnter the electronic mail address of the named contact.zhouquan8519@163.com |
||||||||||||||||||||||||||||||||||||
8 |
Named contact addressEnter the full postal address for the named contact.Department of Obstetrics and Gynecology, the First People’s Hospital of Yichang, 2, Jie-fang Road, Yi Chang, 443000, Hubei, China. |
||||||||||||||||||||||||||||||||||||
9 |
Named contact phone numberEnter the telephone number for the named contact, including international dialing code.+86 15090921512 |
||||||||||||||||||||||||||||||||||||
10 |
Organisational affiliation of the reviewFull title of the organisational affiliations for this review, and website address if available. This field may be completed as 'None' if the review is not affiliated to any organisation.The People’s Hospital of Three Gorges University/The First People’s Hospital of Yichang Website address:http://www.ycyy.com.cn |
||||||||||||||||||||||||||||||||||||
11 |
Review team members and their organisational affiliationsGive the title, first name and last name of all members of the team working directly on the review. Give the organisational affiliations of each member of the review team. |
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
12 |
Funding sources/sponsorsGive details of the individuals, organizations, groups or other legal entities who take responsibility for initiating, managing, sponsoring and/or financing the review. Any unique identification numbers assigned to the review by the individuals or bodies listed should be included.National Natural Science Foundation of China (no. 81401187) |
||||||||||||||||||||||||||||||||||||
13 |
Conflicts of interestList any conditions that could lead to actual or perceived undue influence on judgements concerning the main topic investigated in the review.Are there any actual or potential conflicts of interest?None known |
||||||||||||||||||||||||||||||||||||
14 |
CollaboratorsGive the name, affiliation and role of any individuals or organisations who are working on the review but who are not listed as review team members. |
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Review methods | |||||||||||||||||||||||||||||||||||||
15 |
Review question(s)State the question(s) to be addressed / review objectives. Please complete a separate box for each question.We conducted a systematic review and meta-analysis to investigate the clinical values, including clinicopathology, prognosis, and diagnosis, of neutrophil to lymphocyte ratio in ovarian cancer. |
||||||||||||||||||||||||||||||||||||
16 |
SearchesGive details of the sources to be searched, and any restrictions (e.g. language or publication period). The full search strategy is not required, but may be supplied as a link or attachment.We will search the following electronic bibliographic databases: MEDLINE, EMBASE, The Cochrane Library (the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials (CENTRAL), and the Cochrane Methodology Register) and Web of Science (Science and Social Science Citation Index). The search strategy will include only terms relating to or describing the intervention, and the terms will be combined with the Cochrane MEDLINE filter for controlled trials of interventions. The search strategy for MEDLINE will be made available in the published protocol. The search terms will be adapted for use with other bibliographic databases in combination with database-specific filters for controlled trials, where these are available. There will be no language restrictions. Studies published between January 1990 and the date the searches are run will be sought. The searches will be re-run just before the final analyses and further studies retrieved for inclusion. |
||||||||||||||||||||||||||||||||||||
17 |
URL to search strategyIf you have one, give the link to your search strategy here. Alternatively you can e-mail this to PROSPERO and we will store and link to it.I give permission for this file to be made publicly availableYes |
||||||||||||||||||||||||||||||||||||
18 |
Condition or domain being studiedGive a short description of the disease, condition or healthcare domain being studied. This could include health and wellbeing outcomes.Ovarian cancer; ovarian neoplasms. |
||||||||||||||||||||||||||||||||||||
19 |
Participants/populationGive summary criteria for the participants or populations being studied by the review. The preferred format includes details of both inclusion and exclusion criteria.Adolescents (under 18 years of age) and elderly people (over 70). OC diagnosed according to histopathological examination. |
||||||||||||||||||||||||||||||||||||
20 |
Intervention(s), exposure(s)Give full and clear descriptions of the nature of the interventions or the exposures to be reviewedTo investigate the association of pre-treatment NLR and clinicopathology, overall survival (OS), disease-free survival (DFS) and diagnostic value. |
||||||||||||||||||||||||||||||||||||
21 |
Comparator(s)/controlWhere relevant, give details of the alternatives against which the main subject/topic of the review will be compared (e.g. another intervention or a non-exposed control group).To investigate the association of pre-treatment NLR and clinicopathology, overall survival (OS), disease-free survival (DFS) and diagnostic value. |
||||||||||||||||||||||||||||||||||||
22 |
Types of study to be includedGive details of the study designs to be included in the review. If there are no restrictions on the types of study design eligible for inclusion, this should be stated.To investigate the association of pre-treatment NLR and clinicopathology, overall survival (OS), disease-free survival (DFS) and diagnostic value. |
||||||||||||||||||||||||||||||||||||
23 |
ContextGive summary details of the setting and other relevant characteristics which help define the inclusion or exclusion criteria. |
||||||||||||||||||||||||||||||||||||
24 |
Primary outcome(s)Give the most important outcomes.Overall survival (OS) and disease-free survival (DFS). Give information on timing and effect measures, as appropriate.
|
||||||||||||||||||||||||||||||||||||
25 |
Secondary outcomesList any additional outcomes that will be addressed. If there are no secondary outcomes enter None.Clinicopathology and diagnostic value. |
||||||||||||||||||||||||||||||||||||
Give information on timing and effect measures, as appropriate. |
|||||||||||||||||||||||||||||||||||||
26 |
Data extraction (selection and coding)Give the procedure for selecting studies for the review and extracting data, including the number of researchers involved and how discrepancies will be resolved. List the data to be extracted. |
||||||||||||||||||||||||||||||||||||
27 |
Risk of bias (quality) assessmentState whether and how risk of bias will be assessed, how the quality of individual studies will be assessed, and whether and how this will influence the planned synthesis.The Newcastle-Ottawa Quality Assessment Scale (NOS) will be used to assess the quality of each study by two independent investigators. The NOS consists of three parts: selection (four points), comparability (two points), and outcome assessments (three points). NOS scores >=7 are considered to indicate high-quality studies. |
||||||||||||||||||||||||||||||||||||
28 |
Strategy for data synthesisGive the planned general approach to be used, for example whether the data to be used will be aggregate or at the level of individual participants, and whether a quantitative or narrative (descriptive) synthesis is planned. Where appropriate a brief outline of analytic approach should be given.All the survival results will be estimated as hazard ratios (HR) for each study. If possible, the HR and the 95% confidence intervals (95% CI) will be obtained directly from each study. If the data has not been directly reported, a mathematical estimation will be conducted by calculating the necessary data according to the methods published by Palmer et al., and the Cochran’s Q test and Higgins' I-squared statistic will be used to evaluate the heterogeneity of the pooled results. A p < 0.10 in the Q-test will suggest significant heterogeneity among the studies and the random-effects model (DerSimonian-Laird method) will be applied in this case to calculate pooled HRs. Otherwise, the fixed-effects model (Mantel-Haenszel method) will be used. |
||||||||||||||||||||||||||||||||||||
29 |
Analysis of subgroups or subsetsGive any planned exploration of subgroups or subsets within the review. ‘None planned’ is a valid response if no subgroup analyses are planned.To explore the potential sources of heterogeneity among studies, meta-regression will be conducted utilizing variables such as year of publication, ethnicity, cancer type, analysis method and cutoff value. |
||||||||||||||||||||||||||||||||||||
Review general information | |||||||||||||||||||||||||||||||||||||
30 |
Type and method of reviewSelect the type of review and the review method from the drop down list.Prevention, Prognostic, Systematic review |
||||||||||||||||||||||||||||||||||||
31 |
LanguageSelect the language(s) in which the review is being written and will be made available, from the drop down list. Use the control key to select more than one language.English, Chinese-HK Will a summary/abstract be made available in English?Yes |
||||||||||||||||||||||||||||||||||||
32 |
CountrySelect the country in which the review is being carried out from the drop down list. For multi-national collaborations select all the countries involved. Use the control key to select more than one country.China |
||||||||||||||||||||||||||||||||||||
33 |
Other registration detailsGive the name of any organisation where the systematic review title or protocol is registered together with any unique identification number assigned. If extracted data will be stored and made available through a repository such as the Systematic Review Data Repository (SRDR), details and a link should be included here. |
||||||||||||||||||||||||||||||||||||
34 |
Reference and/or URL for published protocolGive the citation for the published protocol, if there is one.Give the link to the published protocol, if there is one. This may be to an external site or to a protocol deposited with CRD in pdf format.
I give permission for this file to be made publicly availableYes |
||||||||||||||||||||||||||||||||||||
35 |
Dissemination plansGive brief details of plans for communicating essential messages from the review to the appropriate audiences.Do you intend to publish the review on completion?Yes |
||||||||||||||||||||||||||||||||||||
36 |
KeywordsGive words or phrases that best describe the review. (One word per box, create a new box for each term) |
||||||||||||||||||||||||||||||||||||
37 |
Details of any existing review of the same topic by the same authorsGive details of earlier versions of the systematic review if an update of an existing review is being registered, including full bibliographic reference if possible. |
||||||||||||||||||||||||||||||||||||
38 |
Current review statusReview status should be updated when the review is completed and when it is published.Ongoing |
||||||||||||||||||||||||||||||||||||
39 |
Any additional informationProvide any further information the review team consider relevant to the registration of the review. |
||||||||||||||||||||||||||||||||||||
40 |
Details of final report/publication(s)This field should be left empty until details of the completed review are available.
|